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Abstract: An effective prophylactic HIV-1 vaccine is needed to eradicate the HIV/AIDS pandemic but designing such a 
vaccine is a challenge. Despite many advances in vaccine technology and approaches to generate both humoral and 
cellular immune responses, major phase-II and -III vaccine trials against HIV/AIDS have resulted in only moderate 
successes. The modest achievement of the phase-III RV144 prime-boost trial in Thailand re-emphasized the importance of 
generating robust humoral and cellular responses against HIV. While antibody-directed approaches are being pursued by 
some groups, others are attempting to develop vaccines targeting cell-mediated immunity, since evidence show CTLs to 
be important for the control of HIV replication. Phase-I and -IIa multi-epitope vaccine trials have already been conducted 
with vaccine immunogens consisting of known CTL epitopes conserved across HIV subtypes, but have so far fallen short 
of inducing robust and consistent anti-HIV CTL responses. The concepts leading to the development of T-cell epitope-
based vaccines, the outcomes of related clinical vaccine trials and efforts to enhance the immunogenicity of cell-mediated 
approaches are summarized in this review. Moreover, we describe a novel approach based on the identification of SIV and 
FIV antigens which contain conserved HIV-specific T-cell epitopes and represent an alternative method for developing an 
effective HIV vaccine against global HIV isolates. 
Keywords: Vaccine, clinical trials, HIV, SIV, FIV, multi-epitope, conserved epitopes. 
INTRODUCTION 
 While developing a successful HIV vaccine would 
arguably be the best method of eradicating the AIDS 
pandemic, designing such a vaccine is proving to be one of 
the most significant challenges of the 21
st
 century. Since the 
discovery of the virus in 1983 [1], HIV-1 has infected more 
than 60 million individuals and caused greater than 25 
million deaths, most of which have occurred in sub-Saharan 
Africa [2]. Though control of new HIV infections has 
improved due to major global efforts towards preventive 
education and access to antiretroviral therapies, new 
infection rates are still high and the disease remains a 
significant burden in countries with high HIV-prevalence 
[3]. 
 Over the past several decades, the primary focus of HIV 
vaccine research has evolved away from designing a 
traditional antibody-based vaccine towards a more balanced 
approach that would activate both humoral and cell-mediated 
immune (CMI) responses in vaccine-induced protection  
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[4,5]. New delivery systems, novel immunization regimens, 
and a wide selection of formulations for immunogens and 
adjuvants have been developed. It is now quite clear that a 
careful choice of vaccine immunogens capable of affording 
protection against many variants of HIV is important. Not 
only must they protect against existing variants, they must 
also be able to confront a virus with an extraordinarily high 
mutation rate, a function that drives a continuum of 
increasing antigenic diversity. This article briefly discusses 
ongoing research in T-cell-based HIV vaccines and clinical 
trials that focused on CMI activation. We also describe a 
new approach to selecting vaccine immunogens based on 
conserved cytotoxic T lymphocyte (CTL) epitopes. 
WORKING TOWARDS AN HIV VACCINE 
 While some of the most effective vaccines in use today 
have been based on attenuating the viral pathogen, concerns 
regarding the potential for reversion to a virulent form of 
HIV have made the development of an attenuated HIV 
vaccine unfeasible [6]. Similar concerns related to the safety 
of inactivated whole viral vaccines have reduced support for 
a killed HIV vaccine [7]. Challenges to the development of 
an effective HIV vaccine based on subunits, rather than 
whole virus include the enormous diversity of viral 
sequences and the rapid rate of viral evolution that allows 
HIV to evade protective immune responses [8,9]. Despite 
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recent successes in the identification of broadly cross-
reactive neutralizing antibodies (bNAbs) against HIV-1[10], 
current methods for inducing these antibodies have not been 
successful [11]. Furthermore, much remains to be learned 
regarding virus/host interactions and the exact immune 
correlates of protection; these remain some of the most 
formidable obstacles to the design of an effective HIV 
vaccine [12]. 
 Nevertheless, HIV researchers have made substantial 
progress in understanding the evolution, pathogenesis, and 
immunological responses to the virus through preclinical and 
clinical studies in humans and animals [13]. These advances 
have been achieved by studying a variety of human 
populations such as vaccinated volunteers, HIV-exposed 
seronegative individuals (HESN), and different clinical 
groups of HIV-infected individuals (rapid progressors, elite 
controllers, and long-term survivors or non-progressors, see 
below). Experimental vaccine studies have also been 
conducted in animals. For example, immune responses to 
simian immunodeficiency virus (SIV) and recombinant 
SHIV have been extensively studied in macaques [14-16]. A 
viral infection that resembles HIV, equine infectious anemia 
virus (EIAV) has been studied in horses [17], and similarly, 
caprine arthritis encephalitis virus (CAEV) has been the 
subject of extensive research in goats [18,19]. Our group has 
focused on elucidating immune responses to feline 
immunodeficiency virus (FIV) in cats [20,21]. More 
recently, HIV viral vectors have been used to study cell-
mediated immune responses in rodent models, and the hu-
SCID mouse has been considered as a potential model for 
vaccine development [22-25] (Table 1). New approaches and 
technologies utilized in HIV research are advancing science 
in a multidisciplinary way to face the ongoing scientific 
challenges of developing both an HIV vaccine and 
immunotherapeutic strategies. 
MAJOR PHASE-II AND PHASE-III CLINICAL 
VACCINE TRIALS 
 VAX004, which was initiated in 1998, was the first 
phase-III human trials to be conducted. The immunogens for 
this study were recombinant surface envelope glycoproteins 
(gp120) from two HIV-1 subtype-B viruses (AIDSVAX 
B/B) [26] (Table 2). The second phase-III trial VAX003, 
initiated in 1999, used HIV-1 subtype-B and subtype-E 
glycoproteins (AIDSVAX B/E) as immunogens [27,28]. 
Both of these vaccines were designed to stimulate humoral 
immune responses but failed to produce potent neutralizing 
antibodies (NAbs) against clinical HIV isolates and, 
consequently, afforded no protective efficacy. Following 
these two unsuccessful attempts, researchers focused on 
means of inducing CTL responses to confer protection. 
These efforts culminated with the STEP vaccine trial (Table 
2). The vaccine used in this study was designed to induce 
strong CMI responses [29]. It consisted of an adenovirus 
serotype-5 (Ad5) vectored HIV-1 gag/pol/nef from three 
subtype B strains (CAM-1 gag, JRFL pol (RT & IN), IIIB 
nef) [30]. 
 Initiated in 2004, the phase IIb trial was terminated 
before completion due to higher HIV infection rates among 
vaccine recipients than among placebo recipients [29,30], 
possibly explained by the Ad5 sero-positivity status and lack 
of circumcision of the men who became infected [29-31]. 
This increased risk of HIV infection was shown to fade over 
time in a four-year follow-up study [32]. Outside of the 
context of vaccination, Ad5-neutralizing antibodies did not 
increase the risk of HIV infection in a high risk population, 
even after adjusting for their circumcision status [33]. 
 RV144, which was initiated in 2004, is the most recently 
completed phase-III vaccine trial. The vaccine consisted of a 
canarypox virus-vectored HIV-1 gag/pol/env for priming and 
the AIDSVAX B/E for boosting. This vaccine was intended 
to induce both humoral and CMI responses and to cover a 
wider range of potential challenge strains. The vector 
expressed both the gag-pr-gp41 genes from subtype-B LAI 
strain and a gp120 from a circulating recombinant isolate 
called CRF01_AE. The phase III trial, which involved more 
than 16,000 subjects, demonstrated only modest overall 
efficacy (31.2%), and a very minimal efficacy (3.7%) in the 
high risk group [34]. Detectable antibodies and lymphocyte 
proliferation responses were observed during the phase II 
trial, where the majority of vaccine recipients also 
demonstrated antibody-dependent cell mediated cytotoxicity 
(ADCC) responses [35,36]. Following phase III, IgG 
antibodies binding to the V1/V2 variable loops of Env were 
found to correlate with protection, while serum IgA to Env 
correlated with increased risk of infection without causing an 
enhancement of infection rates [37,38]. 
 In summary, during the past three decades of HIV 
vaccine research, only three candidate vaccines have 
completed phase-III clinical trials [39], reflecting the need 
for additional research and development of innovative 
approaches. Furthermore, in these phase-III trials, only the 
HIV-1 subtype B (three strains) and a recombined HIV-1 
subtype A/E (gp120 from CRF01_AE) were used as vaccine 
immunogens. Although these strains and subtypes reflect the 
circulating forms of HIV that are more prevalent in the 
Table 1. Animal Models in HIV-1 Research 
 
Animal Models Virus Major Cell Types Infected Major Clinical Disorders Refs.
b
 
Macaques SIV/SHIV Macrophages, CD4? T cells  Immune deficiency, AIDS-like [14-16] 
Cats FIV Macrophages, CD4? T cells, CD8? T cells Immune deficiency, AIDS-like [20,21] 
Horses EIAV Macrophages Autoimmune hemolytic anemia [17] 
Goats CAEV Macrophages  Arthritis,  Encephalopathy  [18,19] 
Rodent models (e.g., hNOG) a HIV-1 (vectors) Macrophage-like cells, CD4? T cells CD4? T-cell loss [22-25] 
aHumanized NOD/SCID/IL2Rnull (hNOG): severely immunodeficient mice that can easily engraft human cells. 
bReference number (Refs.). 
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geographical location of the trials, they may not contain 
optimal immunogens needed for a vaccine effective against a 
wider range of HIV isolates. The relative success of the 
RV144 trial suggests that an HIV vaccine may be possible 
using current technologies. In the next few sections of this 
review, we address aspects of HIV vaccine development and 
propose a path forward that may improve on this modest 
successs. 
POTENTIAL CORRELATES OF PROTECTION 
 An immune correlate of protection can be defined as an 
immune response that is normally associated with protection 
from infection or disease and for which a measurable 
threshold can be defined [40]. In the case of HIV/AIDS, the 
study of HIV-exposed seronegative individuals (HESN) and 
HIV-positive (HIV?) elite controllers (ECs) has provided 
significant insights into the immune correlates of protection 
from infection and disease. Furthermore, studies of the 
RV144 trial have made contributions by defining more 
precise vaccine-induced immune correlates of protection in 
humans. When fully identified these correlates should 
provide a turning point for advancing HIV vaccine 
development [41]. 
 HIV-exposed seronegative is a term that refers to cohorts 
of commercial sex-workers, hemophiliacs, discordant 
couples, intravenous drug-users, and mother-to-child cases, 
who, despite having high risks or documented exposures to 
HIV, have remained uninfected [42]. While a range of 
factors can potentially explain how HESN remain 
uninfected, a range of conditions including genetic 
mutations, T-cell specific HIV responses, CD8
+
 cell antiviral 
activities, components of innate immunity, or intracellular 
intrinsic factors have been considered, but conclusions 
regarding the causes of these conditions are not evident. 
Efforts are currently underway to standardize the above 
studies and assays and explore other avenues [42,43]. 
 Elite controllers have been a major focus of many 
studies. They are HIV? individuals who are able to maintain 
undetectable viral loads (<75 RNA copies/mL) for many 
years without the use of antiretroviral therapy [44]. These 
individuals are relatively rare, representing less than 1% of 
all HIV infections [45]. The majority of ECs exhibit even 
slower rates of CD4? T-cell decrease and slower disease 
progression than regular long-term non-progressors [46-48]. 
CD8? T cells play a central role in controlling HIV 
replication in ECs [49-51]. Selected genetic factors have also 
been associated with an elite control of the viral infection, 
including the CCR5 co-receptor 32 base-pair deletion or the 
killer cell immunoglobulin-like receptors of NK cells 
[48,52]. HLA-B57 and -B27 are also over-represented in EC 
populations and have been correlated with a lower risk of 
disease, as opposed to certain HLA-B35 alleles which are 
associated with a higher risk for disease progression [52,53]. 
Recent results of the International Controller Study, in 
addition to confirming previous findings, showed that the 
major genetic determinants associated with control of HIV 
infection are located in the peptide binding groove of the 
MHC class I molecule (primarily HLA-B), and also 
implicated HLA-C and other polymorphisms linked to NK 
cells [54]. Though these genetic factors can explain about a 
fifth of the variability in virus control, the question remains 
to be answered on whether the induction of the same cellular 
responses can be elicited in individuals who carry different 
HLA alleles [55]. Moreover, HLA-B57 and -B27 are 
associated with rapid disease progression in some 
individuals [56]. 
 CMI responses have been associated with the initial 
control of HIV infection and reflected a non-cytotoxic 
response against the virus [57]. The important role of the 
CD8? CTLs in the control of HIV disease has subsequently 
been reported [58-61]. In addition, CD4? CTLs play an 
important role early in the control of other viral infections 
[62,63]; these have also been shown to be relevant in the 
case of acute HIV infections [64]. Furthermore, a study of 
rabies vaccination has demonstrated that NK cells can serve 
as effectors in acquired or adaptive immunity as a result of 
CD4? T-cell activation [65]. Similarly, NK cells have been 
described in other viral infections to possess key adaptive 
immune features such as memory response and antigen-
Table 2. Immunogens Used in Major Clinical Vaccine Trials 
 
Vaccine Trial Phase 
(Vaccine Name) 
Trial 
Location 
HIV-1 Immunogens (Vaccine type) Trial Outcome Refs.
a
 
VaxGen 004 
Phase III 
(AIDSVAX B/B) 
North America Subtype B gp120 (subunit proteins) No efficacy [27] 
VaxGen 003 
Phase III 
(AIDSVAX B/E) 
Thailand Subtypes B & E gp120 (subunit proteins) No efficacy [26, 28] 
Step HVTN 502 
Phase IIb 
(MRKAd5 HIV-1) 
Americas Subtype B Ad5-gag/pol/nef (Ad5 vector ) 
No efficacy 
(enhancement 
of infection) 
[29,30] 
RV144 
Phase III 
(ALVAC-HIV-1 
AIDSVAX B/E) 
Thailand 
Prime - subtype B and A/E 
ALVAC-HIV-gag-pr-gp41-gp120 (canarypox vector) 
Boost - Subtypes B & E gp120 (subunit proteins) 
Some efficacy 
[General population (31.2%) 
[High risk groups (3.7%)] 
[34] 
aReferences (Refs.). 
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specific proliferation [66-68]. Consequently their 
involvement in vaccine design is becoming better 
appreciated. With respect to HIV, NK cells have also been 
associated with the prevention of mother-to-child and 
heterosexual HIV transmission [69,70]. Some studies 
suggest that they may play a role in the control of HIV 
replication by responding to peptides [69,71], and may be 
influenced by the peptide/HLA-B complex via the KIR3DL1 
and KIR3DS1 molecules [55]. 
 The role of antiviral antibodies in HIV infection has been 
demonstrated by passive transfer studies with NAbs, which 
showed that anti-HIV NAbs prevented SHIV infection in 
macaques [72] and by anti-HIV NAbs that delayed virus 
rebound after interruption of antiretroviral therapy (ART) in 
humans [73]. However, ECs showed no significant 
difference in NAbs when compared to patients on ART [74]. 
In addition only low levels of bNAbs have been observed in 
the majority of ECs, a population that is heterogeneous in 
terms of immunological characteristics [75,76]. Neverthe-
less, while ECs can have strong CD8? cell-mediated anti-
HIV responses, their antiviral antibody responses may still 
play a role in the control of HIV replication [77,78]. 
PROPOSED METHODS FOR EFFECTIVE PROTECT-
ION AGAINST HIV: THE T CELL-BASED VACCINE 
 A successful HIV vaccine that is able to control the 
AIDS pandemic could have a variety of positive outcomes, 
such as inducing a “sterilizing” immunity; a transient 
infection that is later cleared; or a long-term control of the 
virus without disease manifestations and without further HIV 
transmission from the vaccinated individuals. The more 
conservative and accepted view is that both humoral and 
CMI responses will be important in such a vaccine. Based on 
the lessons learned from successful vaccines against other 
organisms, one correlate of protection has been a defined 
antibody titer directed against one of the key antigens of 
those organisms [4]. This correlate is usually derived from 
the assessment of immune responses in recovered patients 
who are immune to subsequent infections and serves as a 
benchmark titer for the development of an effective vaccine. 
With those conventional vaccines and immune individuals, 
the induction of specific antibodies is the probable cause of 
protection against future infections [79]. Although CD4? T 
cells participate in the B-cell response and memory, T cells 
in general are thought to play a more dominant role in the 
control of established infections rather than in prophylaxis 
[4]. 
 Induction of antibody responses may be critical to 
developing an effective vaccine, but it has been difficult to 
identify the proper immunogen. Due to the mounting 
difficulties associated with making a conventional antibody-
based HIV vaccine [80], some researchers have returned to 
exploring T-cell-based approaches. Designing T-cell 
mediated vaccines requires careful planning so as to generate 
immune responses in the context of most human leukocyte 
antigens (HLA). HLA molecules differ from one individual 
to another and their prevalence also varies in different 
populations, a factor that has been a cause for concern about 
T cell-mediated vaccines [81]. However, HLA class I and 
class II alleles can be grouped into supertypes which are 
clusters of HLA molecules sharing overlapping peptide 
binding specificity [82,83]; vaccines containing epitopes that 
can be presented by HLA supertypes have a better chance of 
global success. Three HLA class I supertypes (HLA-A2, A3, 
and B7) have the potential to cover 80-90% of the major 
ethnicities [81]. Studies have shown that not all CTL 
responses are equally effective. For example, inclusion of 
epitopes presented by some B7 supertype alleles targeting 
the same epitopes may exert differential pressure on the 
virus [84]. Nonetheless, a T-cell-based vaccine using the 
supertype concept may be able to induce similar qualitative 
T-cell responses against the virus among individuals with 
diverse HLA alleles. 
 Most HIV infections occur via sexual transmission at the 
mucosa [85], which is a replication site and a reservoir for 
the virus [86,87]. Therefore, if CMI is important, an 
effective vaccine should induce protective responses at the 
mucosal surface where the majority of the body’s T cells 
reside [88]. Some researchers have reported that CD8? CTLs 
from the blood and mucosa mirror each other [89], with 
some of them originating from the same clones or sharing 
the same HIV-specific epitopes and MHC restrictions [90]. 
In chronically infected individuals, antigens recognized by 
mucosal T cells are also recognized by peripheral blood 
mononuclear cells (PBMC) with a few exceptions [91,92]. 
As a result, the study of these individuals may help define 
some important correlates of protection that are relevant 
against HIV at the mucosa. 
 Findings from non-human primate studies have shown 
that the picture of the systemic immunity obtained from the 
study of PBMCs may only be a snapshot of the immunity 
present at the mucosa [93,94]. Notably, in a study 
recapitulating human HESN where macaques were 
intentionally exposed to low doses of SIV rectally, potent 
virus-specific CTL responses were induced and readily 
measured in the animals’ intestinal lamina propria 
mononuclear cells in the absence of detectable virus and 
virus-specific humoral and T-cell responses in the blood. 
Importantly, when these responses were present, they were 
universally associated with protection from mucosal 
challenge with much higher doses of virus [95]. One caveat 
still remains at which site immune correlates of virological 
control can be identified. In a recent macaque therapeutic 
trial assessing the effect of a particle mediated DNA vaccine 
administered during antiretroviral therapy, it was shown that 
the breadth of epitope recognition observed in the mucosa, 
but not the blood, correlated with control of virus rebound 
when therapy was stopped [96]. Such findings emphasize the 
need for parallel vaccine trials in macaques and humans to 
better understand the role of mucosal T-cell responses in 
protection and help define surrogate correlates of protection 
in the blood of humans. 
 Based on the studies of HIV? individuals, a protective T-
cell-based HIV vaccine should have a set of defined 
characteristics [40] (Table 3). The vaccine should stimulate 
both CD4
+
 and/or CD8
+ 
T cells [97,98], which should have a 
large T-cell receptor repertoire (TCR) diversity [99], an 
ability to secrete multiple cytokines [100], proliferate [101], 
destroy HIV infected cells or at least suppress viral 
replication ex vivo [102,103]. These cells should express 
markers for central or effector memory functions [104,105], 
and should not express markers of T-cell exhaustion [106]. 
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They should be specific for several Gag epitopes [107,108] 
restricted by HLAs associated with viral control [109] and 
conserved across subtypes [110], particularly since 
mutations in Gag would impair the fitness of the virus [111]. 
This extensive list of attributes are only associated with 
cases of better disease outcome and highlights the difficulties 
of making a vaccine based on T-cell immunity. 
 Lessons learned from the major trials can also help 
design better T-cell vaccines. The possible explanations for 
the lack of efficacy in the STEP study are important factors 
to consider in the context of the anti-HIV immunity 
generated. Pre-existing Ad5-specific cellular responses 
conserved among many adenoviruses were shown to 
mitigate T-cell responses against the HIV-1 insert [115]. 
Individuals with lower Ad5-neutralizing antibodies before 
vaccination generally had higher T-cell responses to one or 
more HIV-1 proteins [30]. Furthermore, the vaccine induced 
a lower frequency of the T-cell responses against the 
conserved HIV epitopes than against the variable epitopes 
[116]. The few favorable notes from the STEP trial are also 
factors to consider. Lower HIV-1 RNA levels were observed 
in vaccine recipients carrying HLA alleles associated with 
control of the virus than for the matched-placebo recipients 
[117]. The vaccine used in the STEP trial (mainly a 
population of men who have sex with men) was 
simultaneously tested in a heterosexual cohort in South 
Africa. In this study, the increased risk of HIV-1 infection 
was not observed, even at higher titers of pre-existing Ad5-
neutralizing antibodies in men. In contrast, favorable CD4? 
T-cell counts were observed at 2 and 3 months after 
infection, and hints of lower viral set points, were observed 
in women [118]. These findings indicate that a careful choice 
of vaccine vector, with focus on conserved HIV-1 epitopes, 
and efforts to increase the breath and magnitude of the 
responses against HIV are likely to improve future T-cell 
vaccines [116]. 
 The Env-antigen in an Ad26/MVA vector vaccination 
has been shown to be essential for protection against a 
heterologous neutralization-resistant SIV challenge in 
primates where protection correlated with Env-binding 
antibodies [119]. A rhesus cytomegalovirus SIV vectored 
(RhCMV) vaccine without Env was able to control a 
pathogenic SIV below detectable levels for more than a year. 
This study also shows that a replicative vector like RhCMV 
can induce SIV-specific effector-memory CD8? T cells 
(TEM) important for early protection, while a non-replicative 
vector like the Ad5 induces central memory T cells (TCM), 
which is useful in the control of viremia [120]. In the human 
RV144 vaccine trial where IgG antibodies to Env correlated 
with protection, the vaccine induced stronger humoral than 
cellular immune responses, along with a predominance of 
CD4? T cells [34-36] including polyfunctional CD4? CTL 
against a V2-Env region [121]. Therefore, a vaccine design 
optimized for also inducing CD8? T-cell responses in 
addition to the CD4? T-cell and humoral responses is likely 
to improve on the current success. 
MULTI-EPITOPE VACCINES TO INDUCE T-CELL 
IMMUNITY AGAINST HIV 
 A multi-epitope vaccine can be defined as a vaccine 
construct containing a string of individual epitopes, designed 
to elicit targeted immune responses to the selected epitopes, 
which can be the most conserved or the most recognized by 
common HLAs [41,122,123]. Computational methods for 
minimizing the generation of junctional immunogenicity in 
between epitopes have been used to construct epitope strings 
[123]. Multi-epitope vaccines have been shown to be 
protective in animal models and in mice against lethal 
challenge doses of vaccinia virus [124-126]. There are 
relatively few multi-epitope CTL vaccines that have 
undergone phase I and II clinical trials against HIV. These 
vaccines were generally safe, but poorly immunogenic 
(Table 4), most likely due to the vaccine vehicle and the 
limited number of epitopes contained in the vaccine. The 
traditional interferon-? (IFN?) ELISpot assay is an assay that 
is widely used in vaccine trials because of its relative 
efficiency, and has been the main method of assessing HIV-
specific T-cell immunogenicity in the majority of the trials 
described in Table 4. 
 A multi-epitope vaccine consisting of a concensus 
subtype-A Gag-p24/p17 linked to a stringed gene of CTL 
epitopes (termed HIVA) has been evaluated in a number of 
different trials from the International AIDS Vaccine 
Initiative (IAVI) including prime-boost designs, as opposed 
to the HIV Vaccine Trials Network (HVTN) and the Agence 
National de Recherche sur le SIDA (ANRS) trials described 
in Table 4 [127,128]. The initial phase I studies of the HIVA 
vaccine were conducted in the UK (IAVI-001, -003, and -
005) [129,130], in parallel with sister studies in Kenya 
(IAVI-002, -004, and -008) and in Uganda (IAVI009, phase 
Table 3. A T-Cell Vaccine Based on Better Disease Outcome in HIV? Individuals 
 
Characteristics of CD4
+
 and/or CD8
+ 
T Cells Refs.
b
 
Have a large T-cell receptor repertoire diversity [99] 
Express markers of central and effector memory functions [104,105] 
Be able to destroy HIV-1 infected cells or suppress HIV-1 replication ex vivo [102,103] 
Be able to proliferate upon HIV antigenic stimulation [101] 
Be polyfunctional in cytokine production upon HIV antigenic stimulation [100] 
Be specific for several Gag epitopes that are restricted by HLAs associated with viral control and conserved across many subtypes [107-111] 
Not express markers of T-cell exhaustion (e.g., PD-1, LAG-3, Tim-3, and CTLA-4)a [106,112-114] 
aProgrammed cell death 1 (PD-1); lymphocyte activation gene 3 (LAG-3); cytotoxic T lymphocyte-associated antigen 4 (CTLA-4); T cell immunoglobulin mucin-3 (Tim-3). 
bReferences (Refs.). 
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I/IIa) [131]. Contrasting results were associated with these 
trials. Even though IFN? responses were induced, they were 
transient, and the vaccine induced responses in a higher 
percentage of vaccinees in the UK (78%, 88%, and 89%) 
than in Kenya (15%, 33%, and 10%) or Uganda (13%). 
Subsequent phase I/IIa studies of IAVI-006 and -010 [132] 
that were conducted with a larger number of volunteers also 
showed poor vaccine immunogenicity, two weeks after the 
last MVA vaccination. These results could have been due to 
low antigen doses or to the timing for testing the 
immunogenicity, as the responses were later observed to 
peak one week after the MVA vaccination, and to diminish 
by the second week. 
 In the IAVI-016 trial, four of eight (50%) DNA-MVA 
vaccine recipients showed positive IFN? and five of eight 
(63%) recipients demonstrated proliferation responses, both 
peaking one week after vaccination [133]. This trial also 
used a cultured IFN?-ELISpot in which PBMCs were 
stimulated with the target antigens and cultured for 11 to 13 
days prior to being tested for immune responses to epitopes 
in the ELISpot assay. This procedure improved detection of 
immunogenicity. A similar approach was recently used in a 
malaria vaccine trial, in which IFN? levels in the cultured 
assay correlated with vaccine-induced protection [138]. 
Subsequently, in the IAVI-016 trial, eight of eight (100%) 
volunteers who received the prime-boost vaccination and 
four of eight (50%) who received two doses of the MVA 
vaccine showed CD4? T-cell specific IFN? responses. In 
addition five of the 12 (42%) responders also had CD8? T-
cell specific IFN? responses to the string of CTL epitopes. 
 Another trial (HVTN-048) consisted of four 
immunizations of a DNA vaccine (expressing a 277-aa 
antigen) containing 21 CTL epitopes. Immune responses to 
the epitopes were monitored up to 18 months after the last 
immunization. Only 1 of 8 (13%) recipients of the highest 
dose of vaccine (4 mg) showed a positive IFN?-ELISpot 
response two weeks after the last immunization. Notably, 
only three CD8? CTL responses were transiently detected 
using the chromium release assay [135]. In the HVTN-056 
trial, the immunogen was a multi-epitope peptide (MEP) 
vaccine consisting of four peptides (27-47 aa) supplemented 
with an adjuvant in the presence or absence of 
granulocyte/macrophage colony-stimulating factor (GM-
CSF). Initially intended as a priming agent for a prime-boost 
vaccine regimen, the vaccine was only weakly immunogenic, 
as only 6 of 80 vaccinees showed a transient IFN? response 
after the second or third vaccination. The use of GM-CSF in 
the formulation did not improve the immunogenicity of the 
vaccine [135]. 
 The ANRS VAC18 was a phase II trial consisting of four 
intramuscular injections of a lipopeptide vaccine. This 
vaccine contained an equal weight mixture of 5 HIV-1 
peptides (19-32 aa) linked to a palmitic acid for easy uptake 
by antigen-presenting cells. A cultured-IFN? assay was used 
to measure immunogenicity. Regardless of the vaccine dose 
administered (50, 150, or 500 μg) IFN? responses to the CTL 
epitopes were repeatedly detected in the majority of vaccine 
recipients for 12 months after the last immunization. 
Proliferative responses were also detected to the CD4? T-cell 
epitopes [136]. This lipopeptide vaccine was also used in a  
 
post-infection immunization study, where it induced new 
CD4? T-cell proliferation and CD8? T-cell IFN? responses in 
HIV-1 infected subjects [139]. 
 The vaccines described above and in Table 4 used only a 
modest number of selected CTL epitopes (21-77). In general, 
these vaccines were unable to induce the desired breadth of 
CD8? CTL responses. This may be related to the HLA-
restriction of the study subjects, even though the multi-
epitope vaccine HVTN-048 and HVTN-056 trials required 
immunized subjects to carry at least one of the HLA alleles 
targeted by the vaccine. In the IAVI-009 trial, the vaccine 
was expected to induce at least two to three CTL-epitope 
responses per individual. An important concern related to 
these vaccines is whether the numbers of epitopes used will 
suffice to induce an effective protection against a wide range 
of global HIV isolates. The impact of immunizing study 
subjects against variant viral isolates cannot be tested until a 
sufficient level of immunogenicity is obtained for the 
vaccine epitopes in the target populations. 
 A different clinical trial (HVTN-064) used a multi-
epitope vaccine consisting of 18 T-helper epitopes 
formulated in aluminum hydroxide. This T-helper vaccine 
was immunogenic in 32 of 47 individuals (68%) by 
intracellular cytokine staining, and the CD4? T-cell 
responses observed were polyfunctional. However when 
administered simultaneously with the same DNA vaccine 
used in the HVTN-048 trial, this vaccine was unable to 
improve the immunogenicity towards the CTL epitopes. This 
may be related to the initial inability of the DNA vaccine 
alone to induce sufficient CTL responses [140]. 
 The HIVA prime-boost vaccination approach has also 
been used as a post-infection immunization strategy in phase 
I trials for HIV-1 infected subjects. Despite initial concerns 
that immunization might boost viral titers, the vaccine was 
safe and effectively induced an expansion of CD4? and 
CD8? T cells specific for vaccine epitopes without viral load 
rebound [141,142]. Another study utilized the ELISpot assay 
to evaluate IFN? secretion in vitro by CD8? T cells 
following stimulation with either the MVA.HIVA vector or 
HIV-1 peptides used in the construct. The PBMCs obtained 
from 81 HESN infants show that MVA.HIVA induced IFN? 
responses in 52% (42/81), but only 15% (12/81) of these had 
IFN? responses to the individual HIV-1 peptides [143]. An 
additional two clinical trials have recently tested the safety 
and immunogenicity of HIVA DNA-MVA vaccination in 48 
healthy Gambian infants born to HIV-1-uninfected mothers 
(NCT00982579 trial) and in 72 healthy Kenyan infants born 
to HIV-1-infected mothers (NCT00981695 trial). These 
results are currently pending. 
IMPROVEMENTS IN MULTI-EPITOPE VACCINES 
 Priming with a DNA vaccine and boosting with a viral 
vector vaccine has previously been shown to be an effective 
way of inducing immunogenicity. Nevertheless, despite the 
rational design and the use of a string of CTL epitopes, the 
HIVA prime-boost vaccination failed to induce strong CTL 
responses in the IAVI trials (Table 4). The string of CTL 
epitopes optimized for processing in a DNA vaccine 
(HVTN-048) as well as a peptide vaccine supplemented with 
adjuvant and GM-CSF (HVTN-056) also failed to induce the  
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Table 4. Phase I and IIa Clinical Trials of HIV CTL Multi-Epitope Vaccine 
 
Trial
a
 
Site  
(# of Subjects 
Enrolled in 
the Study)
b
 
Vaccine Type 
(Regimen)
c
 
Dose/Route DNA 
(mg), MVA (p.f.u.)
d
 
HIV Antigens  
(# of CTL 
Epitopes)
e
 
HIV 
Subtypes 
Involved
f
 
HLA 
Super-
Type of 
CTL 
Epitopes 
Epitope 
Selection 
Method 
(%) IFN?g 
Responders 
Refs.
h
 
IAVI-001 UK (18) DNA (d: 0,21)  0.1 or .05 mg/i.m. 78% 
[129, 
130] 
IAVI-002 Kenya (18) DNA (d: 0,21) 0, 0.1 or 0.5 mg/i.m. 15% [131] 
IAVI-003 UK (8) MVA (d: 0,21) 5x107 p.f.u./i.d. 78% [129] 
IAVI-004 Kenya (18) MVA (mo: 0,1 or 0) 0 or 5x107 p.f.u./i.d. 25% [131] 
IAVI-011 
Switzerland, 
UK, SA (81) 
MVA (mo: 0,2) 
0, 5x106, 5x107 or 
2.5x108 p.f.u./i.d., i.m. 
or s.c. 
6% [132] 
IAVI-005 UK (9) 
p-DNA (d: 0,21)i 
b-MVA 
0.1 or 0.5 mg/i.m. 
5x107 p.f.u./i.d. 
89% [129] 
IAVI-006 UK (119)  
p-DNA (mo: 0) 
b-MVA (mo: 2, 3 or 
5,6) 
0, 0.5 or 2 mg/i.m. 
0 or 5x107 p.f.u./i.d. 
12% [132] 
IAVI-008 Kenya (10) 
p-DNA (d: 0,21) 
b-MVA (mo: 9, 10) 
0.5 or 1 mg/i.m. 
5x107 p.f.u./i.d. 
10% [131] 
IAVI-009 Uganda (50) 
p-DNA(mo: 0,1 or 0) 
b-MVA (mo: 5,8) 
0 or 0.5 mg 1x or 
2x/i.m. 
0 or 5x107 p.f.u./i.d. 
15% [131] 
IAVI-010 
Kenya, UK 
(114) 
p-DNA (mo: 0,1) 
b-MVA (mo: 5,8) 
0.5 mg/i.m. 
0, 5x106, 5x107 or 
2.5x108 p.f.u./i.d. 
3% [132] 
IAVI-016 UK (24) 
p-DNA (mo: 0, 1) 
b-MVA (mo: 2 or 0,1) 
0 or 4 mg/i.m. 
0 or 2.5x108 p.f.u./i.d. 
p24/p17 gene 
[contains TH 
epitopes] 
+ 
24 CTL epitopes 
[p24(6), pol(6), 
nef(8), Env (4)] 
 
A* [A, B, 
C, D, E, F, 
G, H]j 
A2, A3, 
A24, B7, 
B8, B27, 
B44 
 
Most 
common 
HIV 
subtype in 
Kenya 
Conserved 
epitopes 
50% [133] 
0.5 mg 4x/i.m. 0% 
2 mg 4x/i.m. 0% 
HVTN-
048 
USA, 
Bostwana (36) 
DNA (mo: 0,1,3,6) 
4 mg 4x/i.m. 
21 CTL epitopes 
[Gag (4), Pol (8), 
Vpr (1), Nef (2), 
Rev (1), Env (5)] 
+ 
TH epitope (1 
pan-DR) 
A, B, C, D, 
AE, AG 
A2, A3, B7 
Conserved 
Epitopes 
HLA 
coverage 13% 
[134] 
USA (40) 
MEP [peptides + 
adjuvant] (mo: 0,1,3) 
1 mg MEP + 50 μg 
adjuvant 3x/i.m. 
13% 
HVTN-
056 
USA (40) 
MEP [peptides + 
adjuvant + GM-CSF ] 
(mo: 0,1,3) 
1 mg MEP/50 μg 
adjuvant + 
50 ug GM-CSF 3x/i.m. 
4 peptides (55 
CTL epitopes): 
Env-TH/ 
Gag-CTL (5), 
Gag-TH/ 
Gag-CTL (19), 
Env-TH/ 
Nef-CTL (15), 
Env-TH/ 
Gag-CTL (16) 
B* 
A1, A2, 
A3, A24, 
B7, B8, 
B27, B58, 
B62  
Epitope 
clustering 
on LANL 3% 
[135] 
50 μg 4x/i.m. 71%k 
150 μg 4x/i.m. 60% k 
ANRS 
VAC18 
France (99) 
Lipopeptides 
(mo: 0, 1, 3, 6) 
500 μg 4x/i.m. 
5 lipopeptides  
(77 CTL epitopes, 
containing 7 TH 
epitopes):  
[Gag1 (9),  
Gag2 (21), Nef1 
(16),  
Nef2 (21),  
Pol (10)] 
 
A1, A2, 
A3, A24, 
B7, B8, 
B27, B58, 
B62 
Conserved 
regions 
70% k 
[136] 
aAll trials are phase I clinical trials except for the bolded trial numbers which are phase IIa (with subjects not at risks of HIV infection); International AIDS Vaccine Initiative (IAVI); 
HIV Vaccine Trials Network (HVTN); Agence National de Recherche sur le SIDA (ANRS). 
bUnited Kingdom (UK); South Africa (SA); United States of America (USA). 
cPrime (p); boost (b); day (d); month (mo); modified vaccinia Ankara (MVA); multi-epitope peptide (MEP); granulocyte macrophage colony stimulating factor (GM-CSF). iNine of 
the 18 volunteers from IAVI-001 who were primed with HIVA-DNA agreed to receive a boost 9-14 months later. 
dIntramuscular immunization (i.m.); intradermal immunization (i.d.); subcutaneous immunization (s.c.). 
eMHC class I molecules can accommodate CTL epitopes of 8 to 11 aa in length [137]. The p24/p17 represents 73% of the Gag and contains both CTL and T-helper epitopes. The 
pan-DR T-helper epitope is a 13-mer that binds to all common HLA-DR alleles. Each of the four peptides in the MEP vaccine is made up of both TH and CTL epitopes; T helper 
(TH). 
fThe HIV subtypes used in the vaccine. *Consensus sequence. jThe CTL epitopes are present in 50-90% of HIV isolates from the different subtypes. 
gPercentage of vaccinees with detected IFN? ELISpot responses to the CTL epitopes. The responses were detected at different time points, before or after the end of the 
immunization schedule for the IAVI studies; after the last immunization for HVTN 064; and after the 2nd or 3rd vaccination (single time point) for HVTN 056. 
kCultured ELISpot assay results. 
hReferences (Refs.). 
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desired responses in the vaccinees. These results lead to 
concerns about the multi-epitope approach for designing an 
effective HIV vaccine. However, a number of methods for 
improving vaccine immunogenicity and stimulating CD8? T 
cells have yet to be investigated in clinical trials. They 
include, and are not limited to the following: the 
enhancement of epitope by increasing the affinity or cross-
reactivity of the epitopes for MHC and/or TCR [144]; the 
use of multiple cytokine combinations (GM-CSF + IL-12; 
CD86 + GM-CSF + IL-12; IL-15) [145-147]; the use of toll-
like receptor (TLR) modulators such as CpG for DNA 
vaccines [148]; the use of alternate vaccine types and routes 
of administration [35,149-151] including autologous 
dendritic cells as a vaccine delivery system [144]. Several 
approaches might be used in combination, leading to 
improved immunogenicity of multi-epitope vaccine 
candidates. 
 Multi-epitope vaccines can be designed to include HLA 
supertypes for populations with a diverse genetic 
background, and promiscuous epitopes can help limit the 
number of final epitopes without decreasing the genetic 
coverage. Multi-epitope vaccines can include both dominant 
and subdominant epitopes, while avoiding antigenic 
elements that may not be favorable for protection. Even 
moderate successes with this type of vaccine against HIV 
might lead to improvements in future multi-epitope vaccine 
designs, not only against HIV but also against other 
pathogens. 
SELECTION OF HIV IMMUNOGENS AND CONSERVED 
EPITOPES 
 Careful design of vaccine immunogens for protection 
against a wide number of HIV variants will be required to 
deal with the large antigenic diversity. Conserved viral 
antigens, subtype-matched antigens, consensus antigens, 
variants of single antigens and multiple antigens have all 
been used alone or in combination [152,153]. Table 4 shows 
a few examples for each of the strategies. Cross-clade CTL 
responses have been shown to preferentially target the 
conserved regions over the more variable ones [154], and 
these responses have been associated with better HIV disease 
outcomes or no disease manifestation [107,155,156]. The 
most conserved regions of HIV, especially those conserved 
across subtypes [153] or among lentiviruses [21], may be the 
best targets of the immune system for inducing vaccine 
protection. Some of these regions may be protective and are 
less likely to mutate because they hold a functional or 
structural importance to the virus species (possibly to the 
genus); a mutation would induce impairment to viral fitness 
[157,158]. This possibility makes the identification of 
conserved epitopes an important aspect of immunogen 
selection in vaccine design. One means of including these 
conserved regions is to construct polyvalent mosaic proteins 
as vaccine immunogens; thus far, preclinical evaluations of 
the mosaic vaccine have demonstrated great potential for 
broad T-cell responses, across subtypes [153,159,160]. 
 A method of selecting highly conserved regions is to 
identify those with the lowest entropy, which is the lowest 
variability at each aa position. Based on this concept, the 
most conserved HIV proteins have been shown to be (in 
order of lowest variability): integrase (IN), core capsid (Gag-
p24), reverse transcriptase (RT), and protease (PR) (Table 5) 
[161]. They were followed by Vpr, Vif, matrix (Gag-p17), 
Nef, Rev, and the surface envelope (SU-Env). Tat and Vpu 
have the highest variability (Table 5). This observation 
suggests that the selection of conserved vaccine epitopes 
should be done first from IN, Gag-p24, RT, and PR. 
 While Jenner may not have considered functional 
conservation when developing his smallpox vaccine, he can 
be considered to have been the first developer of a vaccine 
that was based on conserved features between two different 
viral species [162]. In a similar fashion, comparisons with 
other lentiviruses could help identify highly conserved 
epitopes that are required for viral function and survival. FIV 
is a lentivirus that is only distantly related to HIV-1, but may 
still be relevant to the evolutionary conserved approach of 
vaccine development because of the shared similarities 
between the HIV and FIV viruses in terms of aa sequence, 
structure, and pathogenesis [20]. A comparison of the aa 
composition of proteins between HIV-1 and FIV 
demonstrates the following percentages of identity/ 
homology: RT, 47/72; IN, 37/65; Gag-p24, 32/63; 
nucleocapsid (Gag-p7), 30/54; PR, 24/48; Gag-p17, 20/50; 
SU-Env, 19/43; transmembrane envelope (TM-Env) 18/42 
[21] (Table 5). The three most conserved proteins are also 
those that have the lowest entropy calculation, as shown in 
Table 5 [161]. Hence, the IN, RT, and Gag-p24 proteins 
appear to be excellent targets for identifying evolutionary 
conserved regions that may also contain conserved T-cell 
epitopes. 
IDENTIFICATION OF EVOLUTIONARY CONSERVED 
HIV CTL EPITOPES: USE OF FIV PROTEINS 
 Immunoninformatics has become an integral part in the 
design of new vaccines with great promise of rapid and 
effective vaccine discovery [163-165]. A number of tools 
and databases are now available online including HLA class-
I and -II binding predictions [166,167], and a number of 
tools that are useful for the prediction of CTL epitopes 
(Table 6). In one study performed by our group, NetCTL-1.2 
Table 5. HIV-1/FIV Proteins 
 
 IN* Gag-p24* RT* PR Gag-p17 SU-Env Refs.
c
 
Approximate average entropy scores a 0.16  0.18 0.21 0.23  0.45 0.6 [161] 
HIV/FIV protein % aa identity/homology b 37/65  32/63  47/72  24/48  20/50  19/43 [21] 
aThe average Shannon entropy score is the average value of variability of a given protein at each aa position, calculated by using many aligned sequences. The approximate values 
shown are derived from the figure of HIV-1 (group M) protein variability from Yusim et al. [161], where the proteins are presented from lowest to highest variability. Lower scores 
represent lower variability and therefore higher aa conservation. 
bThe percentage of aa identity and homology between HIV and FIV proteins are shown, with the three most conserved HIV and FIV proteins with *. 
cReferences (Refs.). 
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was used to identify CTL epitopes on the integrase 
sequences of HIV, SIV and FIV (Fig. 1A). For the twelve 
HLA supertypes shown in Fig. (1), a large number of CTL 
epitopes were predicted on each integrase sequence 
regardless of the virus: HIV with 78 epitopes, SIV with 74 
epitopes, and FIV with 85 epitopes. Some of these were 
conserved between HIV and SIV (34 epitopes), as well as 
between HIV and FIV (25 epitopes) (Fig. 1B). A smaller 
number (17 epitopes) was conserved among all three viruses, 
reducing the target epitopes to the expected most 
evolutionary conserved. 
 Thirteen HIV CTL epitopes termed best-defined CTL 
epitopes have been identified empirically on HIV integrase 
by different laboratories and compiled on the Los Alamos 
National Laboratory (LANL) website (Table 7). In this 
regard, based on observations using SIV and FIV, an 
evolutionary conserved HIV CTL epitope can be defined as a 
CTL epitope with a direct or indirect SIV and/or FIV CTL 
counterpart (Fig. 2). Using the direct counterpart approach 
(Fig. 2, arrow a), three of these epitopes are predicted to be 
CTL epitopes conserved between HIV, SIV, and FIV and 
one was shown to be an indirect FIV counterpart (Table 8). 
They share the same HLA binding and CTL supertype 
predictions [169,171]. As illustrated in Fig. (2), an 
evolutionary conserved epitope may be located on an HIV 
protein different from that of FIV (Fig. 2, arrow c). An 
indirect counterpart to an HIV epitope (bolded in Table 8), 
located upstream on FIV integrase, has higher aa identity and 
homology than the direct counterpart (Fig. 2, arrow b). This 
indirect FIV counterpart has the same binding alleles and 
predicted CTL supertype as the HIV epitope. 
 
Table 6. CTL-Epitope Prediction Tools 
 
Name Website Developer Refs.
a
 
CTLPred http://www.imtech.res.in/raghava/ctlpred/ India [168] 
NetCTL http://www.cbs.dtu.dk/services/NetCTL/ Denmark [169] 
NetCTLpan http://www.cbs.dtu.dk/services/NetCTLpan/ Denmark [170] 
aReferences (Refs.). 
 
Fig. (1). NetCTL-1.2 prediction of HIV, SIV, and FIV CTL epitopes. NetCTL-1.2, which is based on proteosomic C-terminal cleavage, TAP 
transport efficiency, and epitope binding to MHC class I alleles, was used to predict CTL epitopes shown by HLA supertypes 
(http://www.cbs.dtu.dk/services/NetCTL/).The total number of predicted epitopes by HLA supertype (A): HIV (78), SIV (74), and FIV (85) 
were tallied after analysis of the full-length integrase sequence from each virus. The predicted CTL epitopes were compared and the 
conserved epitopes between the viruses were identified based on aa position and same predicted HLA supertype (B): HIV-SIV (34), HIV-
FIV (25), and HIV-SIV-FIV (17). 
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 The predicted results of SIV sequences can be explained 
by the high aa identity between HIV and SIV as SIV is more 
closely related to HIV than FIV. However, despite the 
relatively lower aa identity between HIV and FIV, FIV 
counterpart epitopes still appear to be potentially effective 
HIV antigens (see Table 8), most likely due to the slightly 
higher aa homology observed between the two viruses. This 
finding indicates the strong potential that both SIV and FIV 
epitopes could induce CTL responses in human PBMCs and 
suggest that this type of comparison may lead to the 
identification of evolutionarily conserved CTL epitopes on 
HIV. Therefore, conserved SIV and FIV IN peptides can be 
used as immunogens in vitro to compare and identify 
conserved immune responses generated by the PBMCs of 
HIV? individuals. 
CONCLUSION 
 An effective prophylactic HIV vaccine should probably 
include both humoral and CMI responses, since antibodies 
(bNabs, ADCC antibodies) and CTLs are likely to play 
critical roles in the control of the virus. HIV epitopes that are 
highly conserved are believed to be relevant to viral fitness 
and thus important in the design of a global HIV vaccine. 
The identification of evolutionary conserved linear epitopes 
is feasible for both B and T cells with currently available 
bioinformatic tools, but most bNAbs do not usually target 
linear epitopes. Therefore this approach is more useful for 
identifying T-cell epitopes. Testing for immune responses in 
HIV? individuals and vaccinated volunteers from clinical 
trials can help determine the relevance of these epitopes in 
Table 7. Best Defined CTL Epitopes on HIV Integrase
a 
 
 Epitope Position on HXB2 HLA 
1 LPPIVAKEI 28-36 B42 
2 THLEGKIIL 66-74 B*1510 
3 STTVKAACWW 123-132 B57 
4 IQQEFGIPY 135-143 B*1503 
5 VRDQAEHL 165-172 Cw18 
6 KTAVQMAVF 173-181 B*5701 
7 AVFIHNFKRK 179-188 A*0301, A*1101 
8 FKRKGGIGGY 185-194 B*1503 
9 KRKGGIGGY 186-194 B*2705 
10 IIATDIQTK 203-211 A*1101 
11 KIQNFRVYY 219-227 A*3002 
12 VPRRKAKII 260-268 B42 
13 RKAKIIRDY 263-271 B*1503 
aAdapted from LANL (http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html) which was last updated on 2009-08-31. The best defined CTL epitopes or “A 
list” represent the epitopes whose specific HLA class I allele has been demonstrated with strong certainty and are judged to be at their optimal length. 
 
 
Fig. (2). Possible Location of Counterpart Epitopes. 
HIV proteins (A, B) aligned to FIV proteins (A, B) showing four HIV epitopes (h1, h2, h3, h4) and three FIV epitopes (f1, f2, f3) with 
arrows indicating the location of the direct counterpart (arrow a) and indirect counterpart epitopes (arrows b, and c). 
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protection against the virus. Conserved CTL epitopes could 
be used to supplement HIV protein vaccines or used as part 
of a prime-boost combination, which has so far provided the 
best efficacy in a phase-III trial. An effective prophylactic T-
cell vaccine containing highly conserved epitopes may 
inform therapeutic strategies and help the millions of HIV-
infected individuals to effectively control viral replication 
with or without ART.  
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Table 8. HIV-1 Integrase CTL Epitopes and Direct FIV Counterparts 
 
Allele 
(Supertype) 
Virus Epitopes
a
 Iden.
b
 Hom.
b
 
IEDB Prediction: Binding 
Allele (nM Value)
c
 
Supertype  
(Total # of Binding Alleles) 
NetCTL 
Supertype 
B*1510 (B39) HIV THLEGKIIL    B*3901(9); B*1501(425) B39(2) B39 
 SIV THLEGKIII 78 100  B*3901(44) B39(1) B39 
 FIV THFNGKIII 56 78  B*3901(64); B*1501(373)  B39(2) B39 
A*0301 (A3) 
A*1101 (A3) 
HIV MAVFIHNFK    A*0301 (363); A*1101 (20)  A3(5); A1(1) A3 
 SIV MAVHCMNFK  67 67  A*0301(174); A*1101(25) A3(4); A1(1) A3 
 FIV LALYCLNFK 44 78  A*3001(113); A*1101(55) A3(3); A1(1) A3 
B42 (B7) HIV VPRRKAKII    B*0702(43); B*0801(53)  B7(1); B8(1)  B7; B8 
 SIV VPRRKAKII 100 100  B*0702(43); B*0801(53)  B7(1); B8(1)  B7; B8 
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